Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,266
datasets available to search
ShareScore release 0.9.0
Dataset results
3,266 results for “Combination therapy”
PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma
ClinicalTrials.gov study NCT03226249. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
ClinicalTrials.gov study NCT02040857. IPD Sharing: NO. Countries: 1. Publications: 1.
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
ClinicalTrials.gov study NCT00783367. IPD Sharing: Not stated. Countries: 1. Publications: 24.
An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.
ClinicalTrials.gov study NCT02598960. IPD Sharing: Not stated. Countries: 10. Publications: 2.
Intermittent Hypoxia-Hyperoxia Combined With Physical Therapy for Knee Osteoarthritis
ClinicalTrials.gov study NCT06965946. IPD Sharing: YES. Countries: 1. Publications: 7.
Group-Based Behavioral Therapy Combined With Stimulant Medication for Treating Children With Attention Deficit Hyperactivity Disorder and Impaired Mood
ClinicalTrials.gov study NCT00632619. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Therapeutic Effects of Immuno-targeted Therapy Combined With or Without RT for HCC
ClinicalTrials.gov study NCT06639971. IPD Sharing: NO. Countries: 1. Publications: 3.
Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke
ClinicalTrials.gov study NCT00894803. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis B
ClinicalTrials.gov study NCT01369212. IPD Sharing: YES. Countries: 2. Publications: 3.
COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel
ClinicalTrials.gov study NCT03362879. IPD Sharing: UNDECIDED. Countries: 11. Publications: 2.
Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload
ClinicalTrials.gov study NCT00901199. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM
ClinicalTrials.gov study NCT01107717. IPD Sharing: YES. Countries: 1. Publications: 2.
Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
ClinicalTrials.gov study NCT02038647. IPD Sharing: Not stated. Countries: 10. Publications: 1.
Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension
ClinicalTrials.gov study NCT00170950. IPD Sharing: Not stated. Countries: 5. Publications: 5.
A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies.
ClinicalTrials.gov study NCT00462345. IPD Sharing: Not stated. Countries: 1. Publications: 1.
An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma
ClinicalTrials.gov study NCT02253992. IPD Sharing: Not stated. Countries: 4. Publications: 1.
Data from: Phage combination therapies for bacterial wilt disease in tomato
Open the record for dataset details and reuse information.
An anti-influenza combined therapy assessed by single cell RNA-sequencing
<p>Figures source data for<strong> </strong>"<strong>An anti-influenza combined therapy assessed by single cell RNA-sequencing</strong>"</p> <p> </p>
Data from: Clinical outcomes and safety of polymyxin B versus tigecycline combination therapy for pneumonia of carbapenem-resistant Klebsiella pneumoniae: A retrospective cohort study
<p><strong>Purpose:</strong> Infection by carbapenem-resistant <em>Klebsiella pneumoniae</em> (CRKP) has high mortality. There is no clear optimal therapeutic choice for pneumonia caused by CRKP. The aim of this study was to compare the clinical outcomes and safety of the standard doses of polymyxin B-based regimens vs tigecycline-based regimens and to identify risk factors for mortality.</p> <p><strong>Methods:</strong><strong> </strong>This retrospective cohort study included patients with pneumonia caused by CRKP for three years. The primary outcomes were 7-day bacterial eradication rate and 14- and 28-day all-cause mortality. The secondary outcome was incidence of acute kidney injury.</p> <p><strong>Results:</strong><strong> </strong>Seventy-three patients were included in this study, 29 in the<strong> </strong>polymyxin B-based combination therapy group and 44 in tigecycline-based combination therapy group. There were no significant differences between the two groups in terms of the 7-day bacterial eradication rate (31.0% vs 20.5%, <em>P</em>=0.409), the 14-day all-cause mortality (37.9% vs 22.7%, <em>P</em>=0.160), and the incidence of acute kidney injury (14.3% vs 6.8%, <em>P</em>=0.526). The 28-day all-cause mortality in the polymyxin B-based therapy group was higher than in the tigecycline-based group (75.9% vs 45.5%, <em>P</em>=0.010). Binary logistic regression analysis revealed that male and previous use of carbapenems were independent factors associated with 28-day all-cause mortality for patients treated with polymyxin B (<em>P</em><0.05).</p> <p><strong>Conclusions:</strong><strong> </strong>Polymyxin B-based combination therapy at the standard dose should be used with caution for patients with CRKP-induced pneumonia, especially for men who used carbapenems prior to CRKP detection.</p>
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
ClinicalTrials.gov study NCT02436707. IPD Sharing: YES. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.